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Transforming growth factor-b (TGF-b) is a multifunctional
homodimeric polypeptide which acts as a negative growth regu-
lator in most epithelial and endothelial cell types (Massague,
1990). Loss of TGF-b responsiveness is likely to result in deregu-
lated cellular growth in vivo, and is thus thought to be an impor-
tant step in the development of various epithelial tumours (Filmus
and Kerbel, 1993; Markowitz and Roberts, 1996). While it is
firmly established that the growth inhibitory effect of TGF-b is
mediated by a heterodimeric receptor complex comprising two
distinctly related transmembrane serine/threonine kinases (Wrana
et al, 1994), the intracellular components underlying this effect
still require further definition despite extensive documentation of
the involvement of numerous molecules (Polyak, 1996).
It has been suggested that positive growth regulators such as
c-myc, G1 cyclins and cdk4 are molecular targets of TGF-b
(Pietenpol et al, 1990; Ewen et al, 1993; Geng and Weinberg,
1993). The discovery of two families of cyclin-dependent kinase
(cdk) inhibitors provided novel insights into the negative
regulation of cell growth (Nasmyth and Hunt, 1993). Since then,
other cdk inhibitors, namely p27Kip1, p15INK4B and p21WAF1/Cip1 have
been listed as potential cellular mediators in TGF-b-induced cell
cycle arrest (Hannon and Beach, 1994; Polyak et al, 1994a, 1994b;
Datto et al, 1995; Li et al, 1995). The induction or redistribution
of those molecules effectively suppressed their specific G1 cdk–-
cyclin targets.
With regard to this multiplicity of cell cycle regulatory mole-
cules, efforts have been made to unify the actual cellular mecha-
nism responsible for the anti-mitogenic effect of TGF-b. On the
basis of the results with two normal epithelial cell lines (e.g.
Mv1Lu and HaCaT), a model in which the action of cdk inhibitors
is compromised has been suggested (Reynisdottir et al, 1995). It
argues that TGF-b initially induces p15, which then cooperates
with a Kip/Cip cdk inhibitor (p27 or p21), suppressing both major
cell cycle engines (cdk4 and cdk2), and leading to G1 arrest. More
recently, Cdc25A, a cdk activator, has been shown to be rapidly
repressed by TGF-b in human mammary epithelial cells, and has
been suggested as an alternative mechanism of inhibiting cdk4 in
p15-deficient but TGF-b-sensitive cells (Iavarone and Massague,
1997).
Although there is now a better understanding of the potential
involvement of these various cell cycle regulators, the results of
these studies have been derived from a limited set of cell lines.
With regard to the effects of TGF-b on the cyclin–cdk systems, the
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interpretation of most findings has sometimes been hampered
by inconsistent results in different cell systems (Alexander and
Moses, 1995). Whether these cdk inhibitors and cdk activators
play a similar role in all cell types is therefore an important
question.
In the present study, we examined the response of cdk
inhibitors, cdk4 and Cdc25A after TGF-b treatment of gastric
carcinoma cell lines. p21 was found to be the most prominent
CDK inhibitor, being rapidly induced by TGF-b. The response of
p15, Cdc25A and cdk4, however, was delayed or marginal. SNU-
16 cells, which has lost both copies of p15 gene, appears capable
of mediating the TGF-b effect in the absence of p15 via p21. In
both TGF-b-sensitive cell lines, moreover, p21 activation closely
matched the kinetics of G1 arrest. These results provide further
evidence for an initiative role of p21 in the TGF-b-induced
antiproliferative effect on some epithelial cells.
MATERIALS AND METHODS
Cell lines
Four gastric carcinoma cell lines [SNU-1, -5, -16 and -620] were
kindly provided by Dr Jae-Gahb Park of the Department of
Surgery, Seoul National University Hospital. They had been estab-
lished from primary tumours or malignant ascites of gastric cancer
patients, either directly or after heterotransplantation in athymic
nude mice (Park et al, 1990, 1997). Cells were cultured in RPMI-
1640 medium supplemented with 10% fetal bovine serum.
Growth inhibition by TGF-b
Actively growing asynchronous cells were plated into 96-well
plates at a density of 1 ´ 104 cells per well and treated with various
concentrations of up to 200 pM porcine TGF-b1 (R&D) for 72 h.
To compare cellular confluence between individual groups, colori-
metric (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium
bromide (MTT)) assay was performed (Carmichael et al, 1987).
This may reflect the sensitivity of cells to the growth inhibitory
effect of TGF-b.
Cell cycle distribution analysis
To monitor TGF-b-derived changes in the G1 population with
time, crude DNA content of an individual group was measured.
After incubation in the presence of TGF-b for various lengths
of time, TGF-b-sensitive cells were suspended in 1 ml solution of
0.1% sodium citrate and 0.1% Triton X-100 containing 50 mg of
propidium iodide per 1 ml, and then treated with 1 mg ml–1 of
RNAase for 30 min at room temperature. DNA fluorescence was
measured using a FACStar flow cytometer (Becton Dickinson,
San Jose, CA, USA).
Northern blot analysis
Total RNA was isolated from cells according to the acid guani-
dinium isothiocyanate–phenol–chloroform method (Chomczynski
and Sacchi, 1987). For more sensitive visualization of p15 and
Cdc25A transcripts, poly-adenosine (poly-A) RNA was further
extracted using Oligotex mRNA midi kit (QIAGEN GmbH,
Hilden, Germany) according to the manufacturer’s instruction.
Fifteen micrograms of total RNA or 2 mg of poly-A RNA was
electrophoresed on a 1% agarose gel containing 0.66 M formalde-
hyde, before being transferred to a nylon membrane (Nytran;
Schleicher and Schuell, Keene, NH, USA), and cross-linked using
a UV Stratalinker (Stratagene). Blots were hybridized in 50%
formamide, 5 ´ saline–sodium phosphate–EDTA, 0.5% sodium
dodecyl sulphate (SDS), 5´ Denhardt’s solution at 42°C for 20 h.
32P-labelled cDNA probes were prepared by using human p15,
p16, p21, p27, Cdc25A, c-myc and b-actin cDNA fragments as
templates.
Western blot analysis
Cells were washed in phosphate-buffered saline (PBS), and lysed
in TNES buffer (50 mM Tris pH 7.5, 1% NP40, 2 mM EDTA,
10 mM sodium chloride, 20 mg ml–1 aprotinin, 20 mg ml–1
leupeptin, 1 mM phenylmethylsulphonyl fluoride) on ice for
30 min One hundred micrograms of whole cell lysates were
resolved on 12% SDS-polyacrylamide gel, transferred onto nitro-
cellulose membrane (Bio-Rad) by electroblotting and probed with
anti-p21 monoclonal antibody (Oncogene Science), anti-p27
(Transduction Laboratory, Lexington, KY, USA), anti-cdk4 poly-
clonal antibody (Santa Cruz) or anti-Cdc25A polyclonal antibody
(Santa Cruz). The blots were developed by using the ECL kit
(Amersham, Arlington Heights, IL, USA).
Immunoprecipitation and cdk4 kinase assay
After 12 h of TGF-b treatment, SNU-620 cells were lysed in
TNES buffer containing 1 mM sodium vanadate (TNESV buffer).
Immunoprecipitation was performed using 1 mg of polyclonal
anti-cdk4 antibody with 300 mg of cell lysates and was followed
by Western blot analysis for p21. To assess changes in cdk4 kinase
activity, anti-cdk4 immunoprecipitates were prepared after incuba-
tions for various periods with TGF-b, washed several times with
TNESV buffer, then twice with kinase buffer (20 mM Tris, pH 8.0,
10 mM magnesium chloride, 1 mM EGTA). Twenty microlitrss
kinase buffer containing 0.1 mg purified GST-Rb (Kaelin et al,
1991) and 5 mCi [g32P]ATP were then added. The reactions were
incubated for 10 min at 30°C, separated on denaturing gels and
detected by autoradiography.
RESULTS
Growth inhibition of gastric carcinoma cell lines by
TGF-b
To assess TGF-b sensitivity and the dose–response of four gastric
carcinoma cell lines, we measured cellular confluence by MTT
assay after 72 h culture at various concentrations of TGF-b. Two
of four cell lines (SNU-16 and -620) were very sensitive to TGF-b,
while the others (SNU-1 and -5) were resistant (Figure 1). The half
maximal inhibitory concentration (IC50 values) of both sensitive
cells was < 6.25 pM. These growth profiles were consistent with
previous results obtained by DNA synthesis assay (Park et al,
1994).
Change of cell cycle distribution
Cell cycle profiles of the two sensitive cell lines with time
following TGF-b treatment were analysed by flow cytometric
analysis. TGF-b induced G1 arrest quite rapidly, within 6 h, and by1146 SH Kang et al
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24 h had prevented most cells from re-entering the S phase
(Table 1).
Induction of cdk inhibitors by TGF-b
Considering the fast response to TGF-b seen in cell cycle profiles,
it was hypothesized that a cellular mediator would respond earlier
than 6 h. In two separate experiments, RNA expression of various
cdk inhibitors was examined by Northern blot analysis 6 h after
TGF-b treatment. None of the inhibitors were induced in the two
TGF-b-resistant gastric carcinoma cell lines (Figure 2; data not
shown for SNU-5), while p21 mRNA was significantly induced in
both sensitive cell lines (SNU-16 and -620). p15 mRNA levels
also increased in SNU-620, but other CDK inhibitors such as p16
and p27 (Figure 2) and cdk4 (data not shown) were not affected.
p15 and p16 transcription was not detectable in SNU-16, in which
homozygous deletion of both genes had previously been identified
(Lee et al, 1997).
Temporal change in mRNA and protein levels of cell
cycle regulatory molecules in response to TGF-b
In addition to p15 and p21, other cell cycle regulators including
c-myc and Cdc25A have been reported to respond transcriptionally
to TGF-b; all have been implicated in the early events of TGF-b-
induced growth arrest. The time courses of p21, p15, c-myc and
Cdc25A expression in both TGF-b-sensitive cell lines were there-
fore examined by Northern blot analysis using poly-A RNA
(Figure 3). p21 mRNA levels increased within 0.5–2 h of TGF-b
treatment and peaked (at ~25 times the level of controls in SNU-16
and ~52 times in SNU-620) within 6 h, whereas in SNU-620, that
of p15 began to rise and reached its maximum far more slowly.
C-myc mRNA levels were also down-regulated slightly but rapidly
(within 1 h), and then sustained in both cell lines. In particular,
when TGF-b was administered, Cdc25A mRNA levels were
unaffected for the first 6 h, decreased and eventually completely
disappeared. This does not agree, however, with previous findings
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Figure 1 TGF-b sensitivity in four gastric carcinoma cell lines. Cells (1 ´ 104 cells/well) were plated in 96-well plates in the presence of porcine TGF-b1 at
various concentrations. After 3 days, the MTT assay was conducted to determine relative cell numbers. Two cell lines (SNU-16 and -620) were shown to be
highly sensitive to TGF-b. The assay was performed in sextuplicate
Table 1 Changes in cell cycle profiles after TGF-b treatment in the two
gastric cell lines
SNU-16 SNU-620
Time after TGF-b 0 6 12 24 0 6 12 24
treatment (h)
G1 (%) 30.1 38.5 64.1 85.3 53.5 59.3 72.4 86.1
S (%) 57.4 41.2 19.8 11.4 37.6 29.4 18.9 2.2
G2/M (%) 12.5 20.3 16.1 3.3 8.9 11.4 8.7 11.7
p15
p16
p21
p27
b-actin
SNU-1 SNU-16 SNU-620
–+ –+ –+ TGF-b1
Figure 2 Effect of TGF-b on the expression of cdk inhibitors. Northern blot
analysis for several cdk inhibitors in a TGF-b-resistant (SNU-1) and two
sensitive (SNU-16 and -620) cell lines. After 6 h of TGF-b treatment, total
RNAs were extracted from individual cell lines cultured in two separate
flasks. p21 (in SNU-16 and -620) and p15 (only in SNU-620) mRNA levels
were induced by TGF-b (arrowheads indicate changes). Homozygous
deletion of p15 and p16 genes caused the transcripts to be undetectable
despite discernible non-specific bands in p15 panels. Expression of other
cdk inhibitors did not change in any of the cell lines examinedp21 and Cdc25A in the TGF-b effect on gastric cancer cells 1147
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which showed that in mammary epithelial tumour cells, Cdc25A
repression occurred quite rapidly, which is comparable to the
change of c-myc (Iavarone and Massague, 1997).
Rapid p21 protein induction was also observed by Western blot
(Figure 4A). Although the RNA level of p27 was unaffected until
24 h (data not shown), there were changes in protein levels, with
an opposite pattern in both cell lines. Within 12 h of TGF-b treat-
ment, p27 level increased in SNU-16, but showed a marked
decline in SNU-620. cdk4 levels were largely constant during cell
cycle arrest, but in SNU-620, cdk4 disappeared completely after
24 h. Cdc25A protein levels did not decrease in either cell line
within 24 h (Figure 4B).
Increased p21 associates with the cdk4 complex and
inhibits kinase activity
As p21 is a universal cdk inhibitor, TGF-b-induced p21 may asso-
ciate with G1 cyclin kinases (e.g. cyclin D–cdk4 or cyclin E–cdk2
complex). Anti-cdk4 immunoprecipitates were resolved on 12%
SDS-polyacrylamide gel and probed with anti-p21 antibody. We
observed the induced association of p21 with cdk4 in TGF-b-
treated SNU-620 cells compared with untreated cells (Figure 5A),
and also measured the kinase activity of the cdk4 immunoprecipi-
tates using GST-Rb as a substrate. As shown in Figure 5B, rapidly
decreasing phosphorylation of Rb was observed in TGF-b-treated
cells. Because the level of p27 was not increased during that
period, it is assumed that this reduced kinase activity was not
attributable to this cdk inhibitor.
DISCUSSION
G1 cdks, principally the cyclin D1–cdk4 and cyclin E–cdk2
complexes, are known to be responsible for integrating combina-
tions of growth inhibitory signals from different sources, one
of which is TGF-b receptor-generated signals, during G1
(Alexandrow and Moses, 1995). The inhibition of G1 cdk kinase
activity by TGF-b was originally thought to result from
suppressed G1 cyclin or cdk4 synthesis (Ewen et al, 1993; Geng
and Weinberg, 1993). Later, cdk inhibitors such as p27 (Polyak
et al, 1994a, 1994b), p15 (Hannon and Beach, 1994) and p21
(Datto et al, 1995; Li et al, 1995) were shown to be potent cellular
mediators of the inhibitory effect of TGF-b. However, the fact that
there are multiple cell cycle regulators involved in TGF-b action
prompts several questions relating to their actual roles in a certain
cell type, whether they act via redundancy or in a coordinate
manner, and whether their relative importance is largely common
or different depending on cell type.
A previous study involving two different TGF-b-sensitive cell
lines (Mu1Lv mink lung epithelial cells and HaCat human
keratinocytes) offered a unified model in which p15 and a Kip/Cip
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Figure 3 Time course changes in p21, p15, c-myc and Cdc25A mRNA
levels after TGF-b treatment in two TGF-b-sensitive gastric carcinoma cell
lines. For sensitive visualization of faintly expressed transcripts such as p15,
Northern blot analysis was performed using poly-A RNAs. In SNU-620, p21
mRNA level was increased more rapidly (0.5–2 h after TGF-b treatment) than
that of p15, while in both sensitive cell lines down-regulation of Cdc25A
mRNA occurred later (6–10 h after treatment). C-myc mRNA levels were
decreased within 1 h by less than half and were then sustained
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Figure 4 (A) Rapid and prominent induction of p21 protein was also
observed, while changes in p27 levels were different in the two TGF-b-
sensitive cell lines. cdk4 level was constant until 24 h and were then
sustained longer (in SNU-160) or disappeared (in SNU-620). (B) After 24 h,
down-regulation of Cdc25A had not occurred in either cell lines, but in
SNU-16 only occurred within 30 h.
TGF-b
A
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p21 ––
a-cdk4
TGF-b B
0 24 (h) 12 6
pRb
Figure 5 TGF-b led to induced association of p21 with CDK4 and reduced
kinase activity of G1 cyclin–cdk4. (A) After treatment with TGF-b for either
12 h or not at all, SNU-620 whole cell lysates were immunoprecipitated with
anti-CDK4 antibodies and probed with p21 antibodies on Western blot.
(B) SNU-620 cells were treated with TGF-b1 for different times and, from
the lysates, the kinase activities of CDK4 immunoprecipitates were also
assessed using GST-Rb as a substrate. Phosphorylation of Rb was
effectively inhibited in 6 h.
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family molecule (either p27 or p21) cooperate to inhibit cdk func-
tion in response to TGF-b (Reynisdottir et al, 1995). In this model,
an early role of TGF-b-induced p15 was emphasized, since it was
shown to effectively displace p27 from cdk4 as well as suppress
cdk4 kinase activity. The resulting liberated p27, which was then
free to inhibit cyclin E–cdk2 (in Mv1Lu cells), or independently
induced p21 (in HaCaT cells), might suppress cdk2 kinase activity.
Our results showed a different pattern of TGF-b-induced co-
operation among CDK inhibitors in human gastric carcinoma cell
lines. Remarkable induction of p21 was a common feature of the
sensitive cell lines (SNU-16 and SNU-620) in the response to
TGF-b treatment. Induction of p15 mRNA was also seen, albeit in
a more delayed fashion, in SNU-620 cells. In SNU-16 cells, lack
of p15 induction due to homozygous deletion suggests that p15 is
not essential in TGF-b-induced cell cycle arrest. Delay or lack of
p15 induction compared with p21 after treatment with TGF-b in
SNU-620 and SNU-16 indicates that the proposed unifying model
for the role of p15 cannot be applied to human gastric carcinoma
cells. This study demonstrates that the role of individual inhibitors
in TGF-b-induced growth arrest differs according to cell type
(Polyak, 1996).
For both sensitive cell lines, accumulation of cells in G1 by
TGF-b was quite fast and correlated with the induction of p21. In
addition, increased association between p21 and the G1
cyclin–cdk4 complex was demonstrated, as well as decreased
phosphorylation of Rb, which occurred within 6 h following TGF-
b administration. These results suggest that p21 plays a prominent
role in the arrest of cell proliferation caused by TGF-b in gastric
carcinoma cell lines. Moreover, because both TGF-b-sensitive cell
lines utilized in this study possess p53 mutations in both alleles
(Kim et al, 1991; Park et al, 1997), p21 induction by TGF-b is
likely to be p53-independent, as shown by others (Datto et al,
1995).
TGF-b treatment failed to alter mRNA levels of p27 and p16
in the TGF-b-sensitive gastric cell line studies. However, we
observed a distinct change in p27 protein levels. Following TGF-b
treatment, p27 levels increased in SNU-16, but decreased in SNU-
620. Although the current experiment did not provide direct
evidence of G1 cdk inhibition by induced p27, it is likely that p27
and p21 bind to cyclin E–cdk2 and suppress its activity in SNU-16
cells. It appears that, in this case, there is cooperation between p21
and p27, but not between p15 and a Kip/Cip inhibitor. A marked
decrease in p27 protein levels in SNU-620 indicates that p27 might
not play an important role in the mediation of TGF-b in the cells,
even if induced p15 could displace p27 leading to a cdk2–p27
association.
The absence of changes in cdk4 protein levels for 24 h
following TGF-b treatment also indicates that TGF-b-induced
growth arrest is not mediated through decreased synthesis of cdk4.
Delayed disappearance of cdk4 in SNU-620 cells, as shown in
other cases, seems to be an adaptive event, aimed to ensure that the
cells remain arrested (Reynisdottir et al, 1995).
Recently, Cdc25A, a phosphatase essential for G1–S transition,
has also been suggested as a cellular mediator in TGF-b-induced
growth arrest (Iavarone and Massague, 1997). Using the mammary
epithelial cell line MCF10A, which lacks p15 and showed no
induction of cdk inhibitors in response to TGF-b, Iavarone et al
(1997) noted rapid down-regulation of Cdc25A by TGF-b at both
the transcriptional and translational level, an effect comparable
to the kinetics of c-myc. Consistent with this finding, we also
observed distinct down-regulation of Cdc25A mRNA. This event
occurred at a later time when compared to p15 and/or p21 mRNA
induction. Changes in Cdc25A protein levels, however, were
marginal, although Cdc25A protein disappeared after 30 h in
SNU-16 cells. Therefore, in contrast to previous observations,
down-regulation of Cdc25A seems to be less involved in the early
stage of TGF-b-induced growth arrest in gastric carcinoma cells.
Interestingly, a recent study suggested that p21 can compete with
Cdc25A in binding to the cyclin E–cdk2 complex, and as a conse-
quence, it inhibits Cdc25A (Saha et al, 1997). Based on these
results, it can be assumed that Cdc25A could be inactivated by its
competition with induced p21 in gastric carcinoma cells.
In summary, p21 appears to be the most prominent and rapid
intracellular mediator of TGF-b-induced cell cycle arrest in gastric
carcinoma cell lines. One additional induced CDK inhibitor, either
p15 or p27, might be able to cooperate with p21. The more delayed
or marginal down-regulation of cdk4 and/or Cdc25A indicates that
their roles are secondary or adaptive in these cases. This study
provides further evidence for cellular divergence mediating the
growth-suppressive effect of TGF-b by cell cycle regulators (e.g.
cdk inhibitors, cdk4 and Cdc25A). The existence of these multiple
forms of cdk inhibitors may not represent simple redundancy, but
may allow discrimination among different cell types in response to
TGF-b.
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